Summary
The provided AI claims are not verifiable against the supplied FDA label excerpts because the excerpts relate only to thyroid C-cell tumor risk/contraindications and do not contain information supporting or refuting the claims about onset of glucose/weight/appetite effects, titration timing, missed doses, or hypoglycemia risk by concomitant therapies.
Category Scores
Accurate Statements
Unsupported Statements
Mounjaro (tirzepatide) can begin lowering blood glucose within the first doses.
The supplied label excerpts do not provide any information about onset of glycemic lowering after starting doses.
Many people see a change in fasting and overall glucose in the days after starting Mounjaro.
The supplied label excerpts do not provide any information about time course of fasting/overall glucose changes.
The full effect of Mounjaro usually builds over weeks as the body adjusts and doses increase.
The supplied label excerpts do not provide any information about when full effect occurs or whether it builds over weeks with dose increases.
Appetite reduction and cravings can start soon after beginning Mounjaro treatment.
The supplied label excerpts do not provide any information about appetite/craving effects or their onset.
Appetite reduction and cravings often start within the first week or two of Mounjaro treatment.
The supplied label excerpts do not provide any information about timing of appetite/craving effects.
Weight loss from Mounjaro typically happens more gradually.
The supplied label excerpts do not provide any information about expected rate/timing of weight loss.
More noticeable weight changes with Mounjaro typically occur over several weeks to a few months.
The supplied label excerpts do not provide any information about time course of weight changes.
Weight loss over several weeks to a few months occurs as the dose is titrated and the medication’s metabolic effects accumulate.
The supplied label excerpts do not provide any information about titration timing or mechanism-based accumulation contributing to weight loss over that period.
Mounjaro is commonly started at a lower dose and increased stepwise.
The supplied label excerpts do not provide dosing/titration schedules or statements about starting at a lower dose.
Higher doses of Mounjaro often produce a larger effect on appetite and blood sugar.
The supplied label excerpts do not provide dose-response statements about appetite or blood sugar changes.
Even if appetite improves quickly after a dose increase, it still takes time for weight change to show up.
The supplied label excerpts do not provide any information about differential timing of appetite vs weight change after dose increases.
It is common not to feel a dramatic difference immediately, especially early in Mounjaro treatment.
The supplied label excerpts do not provide any counseling about expected immediacy of symptom changes.
If a patient is not seeing any improvement in glucose control after an appropriate period on a stable dose of Mounjaro, they should contact their prescriber.
The supplied label excerpts do not provide guidance about when to reassess glucose control or advise contact with a prescriber based on time on stable dose.
Persistent or severe side effects that limit dosing can occur with Mounjaro.
The supplied label excerpts provided do not include adverse reaction details or statements about dosing-limiting side effects.
The dose schedule often matters for how quickly Mounjaro effects show up.
The supplied label excerpts do not provide any statements connecting dose schedule to speed of effects.
Mounjaro can cause symptoms of low blood sugar.
The supplied label excerpts do not include information about hypoglycemia symptoms or adverse reactions.
The risk of hypoglycemia is higher when Mounjaro is used in combination with insulin.
The supplied label excerpts do not include hypoglycemia risk by concomitant insulin.
The risk of hypoglycemia is higher when Mounjaro is used in combination with a sulfonylurea.
The supplied label excerpts do not include hypoglycemia risk by concomitant sulfonylurea.
Starting at a low titration dose with Mounjaro leads to effects building over time.
The supplied label excerpts do not provide titration dosing or any time-building effects description.
Not taking Mounjaro consistently on schedule can change how quickly results appear.
The supplied label excerpts do not address adherence/timing effects or missed-dose consequences.
Gastrointestinal side effects that lead to slower titration or missed doses can change how quickly results appear.
The supplied label excerpts do not discuss gastrointestinal adverse effects affecting titration or missed doses, nor effects on results timing.
Other diabetes medications can mask or change how glucose improvements are perceived.
The supplied label excerpts do not discuss drug interactions affecting perception/measurement of glucose improvements.
Individual variation can affect how quickly a patient’s body responds to Mounjaro.
The supplied label excerpts do not provide statements about variability in response timing.
Contradictions
Important Omissions
No mention of the label-provided contraindication regarding personal/family history of medullary thyroid carcinoma (MTC) or MEN 2, and no counseling about thyroid tumor symptoms/boxed warning content.
Importance:
High
No mention of the label's thyroid C-cell tumor risk statement from animal data and the uncertainty of human relevance.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The claims make multiple time-course and hypoglycemia-related statements without support from the provided label excerpts. Additionally, important on-label risk information present in the supplied label excerpts (thyroid C-cell tumor risk/contraindications and related patient counseling) is omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims about efficacy onset, appetite/weight timing, titration/adherence effects, and hypoglycemia risk are unsupported by the provided FDA label excerpts; required thyroid C-cell tumor risk/contraindications content from the provided excerpts is omitted.
Suggested Improvement
Limit statements strictly to content present in the provided label excerpts (thyroid C-cell tumor risk/contraindications and counseling). If evaluating other topics (dose schedule, onset of glycemic/weight effects, hypoglycemia risk with insulin/sulfonylurea, missed doses), provide the corresponding FDA label sections.